Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $33.4 million.

  • Corvus Pharmaceuticals' Gains from Investment Securities fell 483.24% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$25.8 million, marking a year-over-year decrease of 5018.48%. This contributed to the annual value of $33.4 million for FY2024, which is 3225.19% up from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $33.4 million for FY2024, which was up 3,225.19% from -$1.1 million recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Gains from Investment Securities high stood at $33.4 million for FY2024, and its period low was -$1.1 million during FY2023.
  • In the last 3 years, Corvus Pharmaceuticals' Gains from Investment Securities had a median value of -$973,000 in 2022 and averaged $10.4 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 197.30% in 2022, then spiked by 3,225.19% in 2024.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Gains from Investment Securities stood at $300,000 in 2020, then spiked by 233.33% to $1.0 million in 2021, then crashed by 197.30% to -$973,000 in 2022, then dropped by 9.76% to -$1.1 million in 2023, then spiked by 3,225.19% to $33.4 million in 2024.